Improving Metabolism With HDL Cholesterol

This study has been completed.
Sponsor:
Collaborator:
Baker Heart Research Institute
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00395148
First received: October 31, 2006
Last updated: May 9, 2011
Last verified: October 2006
  Purpose

High levels of good cholesterol (HDL) in our blood decreases our chance of having a heart attack. This relates in part to the role good cholesterol plays in reducing build up of fat in the arteries. However, good cholesterol has many other protective effects. We have recently identified three enzymes (proteins) activated by HDL in cells lining the blood vessels, which may be responsible for some of HDL's protective actions.


Condition Intervention
Heart Disease
Diabetes
Drug: rHDL

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol

Resource links provided by NLM:


Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • Metabolic parameters

Enrollment: 13
Study Start Date: March 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 - 65 years
  • Free of overt coronary disease
  • Body mass index <35 kg.m-2
  • Fasting plasma glucose > 7 mmol/L-1
  • No major illness

Exclusion Criteria:

  • Unable to give informed consent
  • Smokers
  • Abnormal LFT, U&E, FBE or creatinine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395148

Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Bayside Health
Baker Heart Research Institute
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

Publications:

Responsible Party: Prof Bronwyn Kingwell, Baker IDI Heart & Diabetes Institute
ClinicalTrials.gov Identifier: NCT00395148     History of Changes
Other Study ID Numbers: 175/04
Study First Received: October 31, 2006
Last Updated: May 9, 2011
Health Authority: Australia: Therapeutic Goods Administration

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014